NCT07449377 Evaluation of Fibroscan® Performance in Diagnosing Acute Heart Failure in Patients Presenting to the Emergency Department
| NCT ID | NCT07449377 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Acute Heart Failure (AHF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-04-02 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-04-02 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute heart failure (AHF) is a major cause of acute dyspnea in emergency departments (EDs), driven primarily by venous congestion, which can lead to hepatic congestion and risk of subsequent liver dysfunction. Current diagnostic tools include clinical evaluation, biomarkers, and imaging (Chest X-Ray or echography), are often limited by delayed results, variability, and suboptimal accuracy in emergency settings. Fibroscan®, a non-invasive device originally designed to assess liver stiffness in chronic liver conditions, has shown potential in detecting liver congestion linked to heart failure. Studies have highlighted significant correlations between liver stiffness measurements (LSM) and markers of venous congestion, such as central venous pressure and adverse outcomes in heart failure patients. Preliminary findings suggest that LSM could provide rapid, bedside insights into systemic congestion, offering a promising avenue for improving diagnostic workflows in acute care. While prior research has mainly focused on chronic heart failure or small study populations, further investigation is needed to explore the utility of Fibroscan® in acute presentations of AHF within EDs. This could help address the limitations of existing diagnostic approaches and enhance patient management in time-sensitive environments.
Eligibility Criteria
Inclusion Criteria: 1. Patients ≥18 years 2. ED patients presenting with acute dyspnea and absence of any other obvious cause of dyspnea (for example pneumothorax, acute pneumonia, acute coronary syndrome, Covid) … 3. Social security affiliation (except AME) 4. Informed consent signed Exclusion Criteria: 1. Known chronic liver disease, defined by a Prothrombic time of \< 50%, or any former diagnosis of liver fibrosis. 2. No skin wounds in the abdominal area on which the Fibroscan® will be used 3. History of liver transplantation 4. eGFR \<30 mL/min 5. Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom 6. Pregnancy and breastfeeding 7. Participation in another interventional trial
Contact & Investigator
Amélie VROMANT, Medical Doctor
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT07449377 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Heart Failure (AHF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07449377 currently recruiting?
Yes, NCT07449377 is actively recruiting participants. Contact the research team at amelie.vromant@aphp.fr for enrollment information.
Where is the NCT07449377 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT07449377 clinical trial?
NCT07449377 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Amélie VROMANT, Medical Doctor at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.